Park West Asset Management’s Viking Therapeutics, Inc. VKTXW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-95,600
| Closed | -$449K | – | 239 |
|
|
2021
Q1 | $449K | Hold |
95,600
| – | – | 0.01% | 151 |
|
|
2020
Q4 | $398K | Hold |
95,600
| – | – | 0.01% | 122 |
|
|
2020
Q3 | $414K | Hold |
95,600
| – | – | 0.02% | 92 |
|
|
2020
Q2 | $554K | Hold |
95,600
| – | – | 0.03% | 68 |
|
|
2020
Q1 | $291K | Hold |
95,600
| – | – | 0.02% | 63 |
|
|
2019
Q4 | $623K | Hold |
95,600
| – | – | 0.03% | 74 |
|
|
2019
Q3 | $511K | Hold |
95,600
| – | – | 0.02% | 72 |
|
|
2019
Q2 | $646K | Hold |
95,600
| – | – | 0.03% | 82 |
|
|
2019
Q1 | $800K | Hold |
95,600
| – | – | 0.04% | 88 |
|
|
2018
Q4 | $582K | Hold |
95,600
| – | – | 0.03% | 86 |
|
|
2018
Q3 | $1.53M | Hold |
95,600
| – | – | 0.06% | 91 |
|
|
2018
Q2 | $773K | Hold |
95,600
| – | – | 0.03% | 105 |
|
|
2018
Q1 | $289K | Hold |
95,600
| – | – | 0.01% | 93 |
|
|
2017
Q4 | $242K | Hold |
95,600
| – | – | 0.01% | 87 |
|
|
2017
Q3 | $70K | Hold |
95,600
| – | – | ﹤0.01% | 71 |
|
|
2017
Q2 | $24K | Buy |
95,600
+43,100
| +82% | +$17.2K | ﹤0.01% | 73 |
|
|
2017
Q1 | $26K | Buy |
+52,500
| New | +$22K | ﹤0.01% | 70 |
|
Park West Asset Management's VKTXW Position: Q2 2021 in Review
Park West Asset Management sold out of Viking Therapeutics, Inc. (VKTXW) in Q2 2021, closing a stake of 95,600 shares — an estimated $449K sold.
Park West Asset Management first reported a position in VKTXW in Q1 2017 and held it in 17 quarters. The position peaked at $1.53M in Q3 2018. 0 funds tracked by Wall St. Rank hold VKTXW as of Q2 2021.
- Park West Asset Management reported no remaining Viking Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Park West Asset Management sold 95,600 Viking Therapeutics, Inc. shares in Q2 2021, an estimated $449K.
- Park West Asset Management first reported a position in Viking Therapeutics, Inc. in Q1 2017 and held it in 17 quarters.
- Park West Asset Management's Viking Therapeutics, Inc. position peaked at $1.53M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Viking Therapeutics, Inc. as of Q2 2021.
Based on Park West Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.